Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
HilleVax, Inc (HLVX)
:HLVX
Holding HLVX?
Track your performance easily
HLVX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.55 - $20.22
Previous CloseN/A
Volume43.09K
Average Volume (3M)346.99K
Market Cap
$94.13M
Enterprise Value-$77.42M
Total Cash (Recent Filing)$457.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Mar 14, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.09
Shares Outstanding49,806,070
10 Day Avg. Volume260,365
30 Day Avg. Volume346,985
Standard Deviation0.24
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.53
Forecast
1Y Price Target
$2.33Price Target Upside21.99% Upside
Rating ConsensusHold
Number of Analyst Covering3
HilleVax, Inc News
PremiumCompany Announcements
HilleVax, Inc. Announces Workforce Reduction and Leadership Changes
PremiumCompany Announcements
HilleVax Reports Q3 Financial Results Amid Strategic Planning
PremiumCompany Announcements
HilleVax, Inc. Clears $26.2M Debt and Ends Loan Agreement
Bulls Say, Bears Say
Bulls Say
Debt ManagementNet Debt to Total Capital is at 0%, indicating the company has no debt burden and is financially stable.
Financial PerformanceThe company reported a cash balance significantly higher than its current market cap, highlighting strong financial health.
Research And DevelopmentThe company is actively pursuing the development of norovirus vaccine candidates, showcasing a commitment to innovation and potential growth.
Bears Say
Clinical Trial ResultsThe prior Phase 2B NEST-IN1 trial for HIL-214 in norovirus failed to demonstrate effect across both primary and secondary endpoints, resulting in the discontinued development of HIL-214 in infants.
Cost ManagementManagement continues to wind down costs following the NEST-IN1 infant trial failure.
Efficacy ConcernsThe infant study missed its primary efficacy endpoint for moderate or severe acute gastroenteritis due to the GI.1 or GII.4 norovirus genotypes, and demonstrated no secondary endpoint benefit.
---
HLVX FAQ
What was HilleVax, Inc’s price range in the past 12 months?
HilleVax, Inc lowest stock price was $1.55 and its highest was $20.22 in the past 12 months.
What is HilleVax, Inc’s market cap?
HilleVax, Inc’s market cap is $94.13M.
When is HilleVax, Inc’s upcoming earnings report date?
HilleVax, Inc’s upcoming earnings report date is Mar 14, 2025 which is in 54 days.
How were HilleVax, Inc’s earnings last quarter?
HilleVax, Inc released its earnings results on Nov 07, 2024. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.417 by -$0.103.
Is HilleVax, Inc overvalued?
According to Wall Street analysts HilleVax, Inc’s price is currently Undervalued.
Does HilleVax, Inc pay dividends?
HilleVax, Inc does not currently pay dividends.
What is HilleVax, Inc’s EPS estimate?
HilleVax, Inc’s EPS estimate is -0.38.
How many shares outstanding does HilleVax, Inc have?
HilleVax, Inc has 49,806,070 shares outstanding.
What happened to HilleVax, Inc’s price movement after its last earnings report?
HilleVax, Inc reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.417. Following the earnings report the stock price went down -1.02%.
Which hedge fund is a major shareholder of HilleVax, Inc?
Among the largest hedge funds holding HilleVax, Inc’s share is Deerfield Management Company, LP. It holds HilleVax, Inc’s shares valued at 3M.
---
HilleVax, Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.33 (21.99% Upside)
$2.33 (21.99% Upside)
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.18%
12-Months-Change
Fundamentals
Return on Equity
-62.24%
Trailing 12-Months
Asset Growth
-39.88%
Trailing 12-Months
Company Description
HilleVax, Inc
HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
---
Technical Analysis
EyePoint Pharmaceuticals
―
Fulcrum Therapeutics
―
Immunocore Holdings
―
Revance Therapeutics
―
Tarsus Pharmaceuticals
―
AstraZeneca
―
---